Welcome to Wellness Month! As we celebrate our health and well-being, there's no better time to delve into a recent scientific advancement for menopausal women. Veozah (also known as Fezolinantant), is a non-hormonal menopause-related drug approved by the FDA on May 13,2023. This medication offers relief for women experiencing hot flashes.
The emergence of Veozah is a refreshing approach from the medical community, which historically has done little to support women during menopause. Veozah acts on specific neurotransmitter receptors in the brain, which help regulate body temperature. It is the first neurokinin 3 receptor (NK3R) antagonist to market, and the first non-hormonal treatment to address the neural signaling underlying hot flashes. Veozah’s principal side effect is elevated liver enzymes. Therefore women with liver related damage including kidney disease are not candidates for the drug. According to the FDA other common side effects are diarrhea, insomnia, back pain.
While the approval of Veozah has been met with some enthusiasm, it is essential to recognize that the treatment comes at a price. A 30 day supply can be available for $500 or $6000/year, which would be prohibitive for many women. Consequently, Veozah may not be accessible to everyone, leaving many women searching for alternatives.
As we celebrate Wellness Month, it's exciting to see traditional medicine make advancements in women's health, such as Veozah. Simultaneously, let us not forget the timeless power of Botanicals, which offer a natural, safe, and budget-friendly alternative for managing hot flashes, mood swings and sleeplessness during menopause. In this journey of well-being, informed choices and comprehensive approaches will empower women to embrace their bodies and navigate through this transitional phase with grace and comfort.